Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin Academic Article Article uri icon

Overview

MeSH Major

  • Amyotrophic Lateral Sclerosis
  • Biomarkers
  • Muscle Weakness
  • Nerve Growth Factors
  • Neuropeptides

abstract

  • The oral MDD antiemetic regimen prevented acute emesis in 73% of the patients entered and was well tolerated in this population of patients with small cell lung cancer.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950901)76:5<774::AID-CNCR2820760510>3.0.CO;2-5

PubMed ID

  • 8625179

Additional Document Info

start page

  • 774

end page

  • 8

volume

  • 76

number

  • 5